102 related articles for article (PubMed ID: 9161882)
1. Interleukin-15 acts as an immunological co-adjuvant for liposomal antigen in vivo.
Gursel M; Gregoriadis G
Immunol Lett; 1997 Mar; 55(3):161-5. PubMed ID: 9161882
[TBL] [Abstract][Full Text] [Related]
2. The immunological co-adjuvant action of liposomal interleukin-2: the role of mode of localisation of the cytokine and antigen in the vesicles.
Gursel M; Gregoriadis G
J Drug Target; 1998; 5(2):93-8. PubMed ID: 9588865
[TBL] [Abstract][Full Text] [Related]
3. Liposomes as adjuvants with immunopurified tetanus toxoid: influence of liposomal characteristics.
Davis D; Gregoriadis G
Immunology; 1987 Jun; 61(2):229-34. PubMed ID: 3596639
[TBL] [Abstract][Full Text] [Related]
4. Primary immune response to liposomal tetanus toxoid in mice: the effect of mediators.
Davis D; Gregoriadis G
Immunology; 1989 Oct; 68(2):277-82. PubMed ID: 2509329
[TBL] [Abstract][Full Text] [Related]
5. Liposomes as adjuvants with immunopurified tetanus toxoid: the immune response.
Davis D; Davies A; Gregoriadis G
Immunol Lett; 1987 Apr; 14(4):341-8. PubMed ID: 3583325
[TBL] [Abstract][Full Text] [Related]
6. Liposomes as immunological adjuvants: antigen incorporation studies.
Gregoriadis G; Davis D; Davies A
Vaccine; 1987 Jun; 5(2):145-51. PubMed ID: 3604394
[TBL] [Abstract][Full Text] [Related]
7. Liposome-entrapped T-cell peptide provides help for a co-entrapped B-cell peptide to overcome genetic restriction in mice and induce immunological memory.
Gregoriadis G; Wang Z; Barenholz Y; Francis MJ
Immunology; 1993 Dec; 80(4):535-40. PubMed ID: 7508417
[TBL] [Abstract][Full Text] [Related]
8. Mannose-mediated targeted immunoadjuvant action of liposomes.
Garcon N; Gregoriadis G; Taylor M; Summerfield J
Immunology; 1988 Aug; 64(4):743-5. PubMed ID: 3169846
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant properties of non-phospholipid liposomes (Novasomes) in experimental animals for human vaccine antigens.
Gupta RK; Varanelli CL; Griffin P; Wallach DF; Siber GR
Vaccine; 1996 Feb; 14(3):219-25. PubMed ID: 8920703
[TBL] [Abstract][Full Text] [Related]
10. Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens.
Phillips NC; Gagné L; Ivanoff N; Riveau G
Vaccine; 1996 Jun; 14(9):898-904. PubMed ID: 8843632
[TBL] [Abstract][Full Text] [Related]
11. Liposomal adjuvanticity: effect of encapsulation and surface-linkage on antibody production and proliferative response.
Shahum E; Thérien HM
Int J Immunopharmacol; 1995 Jan; 17(1):9-20. PubMed ID: 7782155
[TBL] [Abstract][Full Text] [Related]
12. Immunoadjuvant action of liposomes: comparison with other adjuvants.
Gregoriadis G; Panagiotidi C
Immunol Lett; 1989 Feb; 20(3):237-40. PubMed ID: 2714847
[TBL] [Abstract][Full Text] [Related]
13. A novel positively-charged lipid 1,2-bis(hexadecylcycloxy)-3-trimethyl aminopropane (BisHOP) enhances the adjuvant effect of liposomes on encapsulated tetanus toxoid.
Tan L; Gregoriadis G
Asian Pac J Allergy Immunol; 1991 Jun; 9(1):21-4. PubMed ID: 1776976
[TBL] [Abstract][Full Text] [Related]
14. The effect of surface-coupled antigen of liposomes in immunopotentiation.
Latif NA; Bachhawat BK
Immunol Lett; 1987 May; 15(1):45-51. PubMed ID: 3610232
[TBL] [Abstract][Full Text] [Related]
15. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4.
Marinaro M; Staats HF; Hiroi T; Jackson RJ; Coste M; Boyaka PN; Okahashi N; Yamamoto M; Kiyono H; Bluethmann H; Fujihashi K; McGhee JR
J Immunol; 1995 Nov; 155(10):4621-9. PubMed ID: 7594461
[TBL] [Abstract][Full Text] [Related]
16. Pertussis toxin enhanced IgG1 and IgE responses to primary tetanus immunization are mediated by interleukin-4 and persist during secondary responses to tetanus alone.
Samore MH; Siber GR
Vaccine; 1996 Mar; 14(4):290-7. PubMed ID: 8744555
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of diphtheria toxoid and poly(I:C) loaded cationic liposomes after hollow microneedle-mediated intradermal injection in mice.
Du G; Leone M; Romeijn S; Kersten G; Jiskoot W; Bouwstra JA
Int J Pharm; 2018 Aug; 547(1-2):250-257. PubMed ID: 29870743
[TBL] [Abstract][Full Text] [Related]
18. Liposomes as vaccine carriers. Incorporation of soluble and particulate antigens in giant vesicles.
Antimisiaris SG; Jayasekera P; Gregoriadis G
J Immunol Methods; 1993 Dec; 166(2):271-80. PubMed ID: 8288880
[TBL] [Abstract][Full Text] [Related]
19. Liposome-mediated DNA vaccination: the effect of vesicle composition.
Perrie Y; Frederik PM; Gregoriadis G
Vaccine; 2001 Apr; 19(23-24):3301-10. PubMed ID: 11312029
[TBL] [Abstract][Full Text] [Related]
20. Liposomes containing NY‑ESO‑1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines.
Cruz LJ; Rueda F; Simón L; Cordobilla B; Albericio F; Domingo JC
Nanomedicine (Lond); 2014 Apr; 9(4):435-49. PubMed ID: 24910875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
